Results 81 to 90 of about 1,254,012 (356)

A randomized trial of bevacizumab for newly diagnosed glioblastoma. [PDF]

, 2014
BACKGROUND: Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma.
Aldape, Kenneth D, Armstrong, Terri S, Blumenthal, Deborah T, Brachman, David G, Brown, Paul D, Chakravarti, Arnab, Colman, Howard, Curran, Walter J, Dignam, James J, Gilbert, Mark R, Jaeckle, Kurt A, Jeraj, Robert, Mehta, Minesh P, Pugh, Stephanie, Schiff, David, Stieber, Volker W, Sulman, Erik P, Tremont-Lukats, Ivo W, Vogelbaum, Michael A, Wefel, Jeffrey S, Werner-Wasik, Maria, Won, Minhee   +21 more
core   +2 more sources

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

FEBS Letters, EarlyView.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo, Catherine S. Palmer, Jacqueline M. Kimmey   +2 more
wiley   +1 more source

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

The role of Lobectomy in Glioblastoma management: A Retrospective series

Brain and Spine
Introduction: Treatment choices for glioblastoma (GB) remain scarce. Multiple clinical studies have demonstrated the importance of supramaximal resection.
Christina K. Arvaniti, Alexandros G. Brotis, Jacob S. Young, Sivani Sivanrupan, Gracia Menna, Masahiro Nishide, Philippe Schucht, Mitchel Berger, Kostas N. Fountas   +8 more
doaj   +1 more source

PF389 PROGRESSION‐FREE SURVIVAL PREDICTS OVERALL SURVIVAL IN FRONTLINE CLL

HemaSphere, 2019
Background:Many phase II and III trials in oncology utilise the surrogate endpoint progression‐free survival (PFS) as the primary endpoint; however, the relationship between a surrogate endpoint and true clinical benefit in terms of overall survival (OS) or quality of life must be demonstrated.Aims:This research aimed to explore and quantify the ...
S. Baculea, S. Horsburgh, S. Chadda, L. Nelson, C. LeReun   +4 more
openaire   +1 more source

Bias in progression‐free survival analysis due to intermittent assessment of progression [PDF]

Statistics in Medicine, 2015
Cancer clinical trials are routinely designed to assess the effect of treatment on disease progression and death, often in terms of a composite endpoint called progression‐free survival. When progression status is known only at periodic assessment times, the progression time is interval censored, and complications arise in the analysis of progression ...
Zeng, Leilei, Cook, Richard J., Wen, Lan, Boruvka, Audrey   +3 more
openaire   +2 more sources

The role and implications of mammalian cellular circadian entrainment

FEBS Letters, EarlyView.
At their most fundamental level, mammalian circadian rhythms occur inside every individual cell. To tell the correct time, cells must align (or ‘entrain’) their circadian rhythm to the external environment. In this review, we highlight how cells entrain to the major circadian cues of light, feeding and temperature, and the implications this has for our
Priya Crosby
wiley   +1 more source

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas

Endocrine Oncology
Objective: Glucagonomas are rare islet cell tumours, accounting for 2% of such tumours, with an annual incidence of 0.01–0.1 per million. This study aimed to describe diagnostic characteristics and treatment outcomes in patients with glucagonoma from a ...
Eleni Armeni, Alexander Branton, Juliana Porto, Dalvinder Mandair, Aimee R Hayes, Aspasia Manta, Shaunak Navalkissoor, Gopinath Gnanasegaran, Ann-Marie Quigley, Ashley B Grossman, Martyn Caplin, Christos Toumpanakis   +11 more
doaj   +1 more source

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer [PDF]

, 2017
Rationale: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%.
Archibugi, Livia, Botticelli, Andrea, Castaldi, Nadia, Falcone, Rosa, Marchetti, Paolo, Mazzuca, Federica, Osti, Mattia Falchetto, Roberto, Michela   +7 more
core   +1 more source

P2.07-07 Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors [PDF]

, 2023
Lei Deng, Changchuan Jiang, Stuthi Perimbeti, Grace K. Dy   +3 more
openalex   +1 more source